The University of Cincinnati Cancer Center\u2019s Trisha Wise-Draper, MD, PhD, will present a late-breaking abstract detailing the trial results at the Society for Immunotherapy of Cancer 40th Anniversary Annual Meeting Nov. 7.<\/p>\n
Oncolytic viruses are specially engineered to infect and destroy cancer cells. The Phase 2 IGNYTE trial is testing RP1, a genetically modified herpes simplex type 1 virus designed to directly destroy tumors and generate a robust antitumor immune response.\u00a0<\/p>\n
The trial is testing RP1 in combination with nivolumab, an immunotherapy drug that targets PD-1 protein receptors on tumors to help the body\u2019s own immune system identify and attack cancer cells.<\/p>\n
Reviewing data from 140 patients enrolled in the trial, Wise-Draper and colleagues found the combination of RP1 and nivolumab led to increased immune response, immune cell infiltration and activation within tumors in patients who had not previously responded to immunotherapy, indicating RP1 helps overcome treatment resistance.<\/p>\n
\u201cThe trial itself was positive in that approximately one-third of the patients with refractory melanoma will respond to this combination, and responses are durable,\u201d said Wise-Draper, professor of medicine in the Division of Hematology\/Oncology, section head of medical oncology, co-leader of the Head and Neck Experimental Advancement Laboratory in UC’s College of Medicine, and deputy director of UC’s Office of Clinical Research. \u201cThis is a promising combination that is well tolerated for patients with PD1 refractory melanoma.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"The University of Cincinnati Cancer Center\u2019s Trisha Wise-Draper, MD, PhD, will present a late-breaking abstract detailing the trial…\n","protected":false},"author":2,"featured_media":168074,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[77384,77382,18,77381,135,19,17,5,172,96462],"class_list":{"0":"post-168073","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-academic-health-center","9":"tag-college-of-medicine","10":"tag-eire","11":"tag-faculty-staff","12":"tag-health","13":"tag-ie","14":"tag-ireland","15":"tag-news","16":"tag-research","17":"tag-university-of-cincinnati-cancer-center"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115509036687695662","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/168073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=168073"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/168073\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/168074"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=168073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=168073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=168073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}